ZBIO — Zenas BioPharma, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1953926 ·
Last close
$26.24
Market Cap
$1.71B
52W High
$44.60
52W Low
$13.50
ADV30
685,080
Next earnings
2026-11-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | — | — | -77,659,000 | — | — | — | — |
| Mar 2026 | 0 | — | -77,350,000 | -80,987,000 | 747,682,000 | 500,224,000 | 411,853,000 |
| Dec 2025 | 0 | — | -71,312,000 | -240,442,000 | 383,640,000 | 110,641,000 | 141,496,000 |
| Sep 2025 | 0 | — | -47,580,000 | -51,499,000 | 322,018,000 | 115,565,000 | 125,590,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-210,478,000
Investing CF
$-134,001,000
Financing CF
$648,660,000
CapEx
$-35,020,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-8.47
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-846,115,000
Inventory
—
Receivables
—
ST Investments
$216,981,000
EBIT TTM
$-407,515,000
Pretax Income TTM
$-425,025,000
Interest Exp TTM
$6,631,000
Analysts
8
Yahoo Snapshot (yfinance, live)
Total Revenue
$1,000,000
EBITDA
$-273,870,016
Free Cash Flow
$-211,391,632
Enterprise Value
$1,683,034,624
Total Cash
$643,126,016
Total Debt
$297,860,992
Shares Out
65,176,723
Trailing EPS
$-9.63
Book Value
$3.90
ROE
-199.0%
ROA
-34.4%
Div Yield
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 10,000,000 | -211,385,000 | -377,737,000 | 383,640,000 | 141,496,000 | 242,144,000 | -172,333,000 |
| Dec 2024 | 5,000,000 | -163,888,000 | -156,988,000 | 369,968,000 | 57,510,000 | 312,458,000 | -119,674,000 |
| Dec 2023 | 50,000,000 | -27,147,000 | -37,124,000 | 68,180,000 | 293,901,000 | -225,721,000 | -30,529,000 |
| Dec 2022 | 0 | -75,199,000 | -119,282,000 | 74,579,000 | 266,865,000 | -192,286,000 | -65,652,000 |
TTM Snapshot
Revenues TTM
$3,018,000
NetIncome TTM
$-425,151,000
OpCashFlow TTM
—
Assets (Latest)
$747,682,000
Forward EPS
$-4.66
Max Pain — expiry 2027-12-17
max pain strike: $20.00 · spot: $27.53 · call oi: 1,137 · put oi: 4,137
Expected Move to 2027-12-17:
±$17.50
(63.57%) —
implied range
$10.03 –
$45.03
· ATM straddle on $30.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| BRVE | Braveheart Bio, Inc. | $1.72B | $19.09 | — |
| SEPN | Septerna, Inc. | $1.72B | $36.90 | — |
| SDGR | Schrodinger, Inc. | $1.73B | $26.39 | — |
| NUVB | Nuvation Bio Inc. | $1.73B | $4.95 | — |
| ANIP | ANI PHARMACEUTICALS INC | $1.65B | $71.98 | — |
News headlines (Yahoo Finance, 1h cache)
Zenas BioPharma Announces Upcoming Presentations of Orelabrutinib Data in Relapsing Remitting Multiple Sclerosis, Clinical Trial Designs in Progressive Multiple Sclerosis and Other Multiple Sclerosis
2026-10-07 11:05 · Yahoo
Zenas BioPharma to Host Virtual R&D Event
2026-10-06 11:05 · Yahoo
Can Zenas BioPharma’s (ZBIO) Clinical Pipeline Justify Its Heavy Cash Burn?
2026-09-23 11:14 · Yahoo
Why Is Zenas BioPharma (ZBIO) Filing More Than $240 Million In Shelves?
2026-09-23 04:32 · Yahoo
Zenas BioPharma Announces Upcoming Presentations of Obexelimab Data in IgG4-Related Disease at the IgG4ward! 6th International Symposium on IgG4-Related Disease and ACR Convergence 2026
2026-09-22 11:05 · Yahoo
Zenas BioPharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
2026-09-18 20:15 · Yahoo
Zenas BioPharma to Present at Upcoming Healthcare Investor Conferences
2026-09-04 11:05 · Yahoo
Zenas BioPharma Bear Case Overlooks Obexelimab's Commercial Potential, Wedbush Says
2026-07-17 12:13 · Yahoo
Zenas BioPharma (ZBIO): Best IPO Stocks with Huge Upside Potential
2026-07-10 13:58 · Yahoo
Zenas BioPharma's CEO Purchased 60,000 Company Shares. Here's a Deeper Look at the Transaction.
2026-06-21 11:31 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.